Salvage therapy with amprenavir, lopinavir and ritonavir is durably potent in HIV-infected patients in virological failure: 1-year results.
We report the results of the extended follow-up at one year of a randomized trial evaluating the virological efficacy of a salvage therapy combining lopinavir and amprenavir with either 200 or 400 mg/day ritonavir, along with optimized nucleoside reverse transcriptase inhibitors, in patients carrying multidrug-resistant isolates. The combination of amprenavir, lopinavir and ritonavir (400 mg/day) is durably potent, yielding a sustained virological response (HIV RNA < 50 copies) in 39% of cases.
Raguin
Gilles
G
Département de Medecine, Hôpital Croix-St-Simon, France.
Poizat
Gwendoline
G
Morand-Joubert
Laurence
L
Taburet
Anne-Marie
AM
Le Tiec
Clotilde
C
Clavel
François
F
Chêne
Geneviève
G
Girard
Pierre-Marie
PM
D019380:Anti-HIV Agents / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active; D002219:Carbamates / Q000627:therapeutic use; D024921:Drug Resistance, Multiple, Viral; D005500:Follow-Up Studies; D005663:Furans; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology; D015497:HIV-1 / Q000187:drug effects; D006801:Humans; D061466:Lopinavir; D011744:Pyrimidinones / Q000627:therapeutic use; D019438:Ritonavir / Q000627:therapeutic use; D016879:Salvage Therapy / Q000379:methods*; D013449:Sulfonamides / Q000627:therapeutic use
D019380:Anti-HIV Agents; D002219:Carbamates; D005663:Furans; D011744:Pyrimidinones; D013449:Sulfonamides; D061466:Lopinavir; C095108:amprenavir; D019438:Ritonavir